| [1] | Baikun LIU, Zhiru WANG, Wenjing ZHAO. Effect of gallic acid in increasing the chemosensitivity of hepatocellular carcinoma HepG2 cells to sorafenib[J]. Journal of Clinical Hepatology, 2025, 41(2): 292-299. doi: 10.12449/JCH250215 |
| [2] | Xing WANG, Tao ZHANG. Value of alpha-fetoprotein response in evaluating the efficacy of sorafenib combined with camrelizumab in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 843-849. doi: 10.3969/j.issn.1001-5256.2023.04.015 |
| [3] | Guoxiang CHEN, Mo ZHOU, Sheng CHEN, Yuan WANG, Yuanlong ZHOU, Jihong YANG. Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 699-703. doi: 10.3969/j.issn.1001-5256.2021.03.040 |
| [4] | Yang Jun, Yin Yu, Ni CaiFang, Zhu XiaoLi, Li Zhi, Zhang Shen, Huang Peng, Wang WanSheng. Value of ABCR scoring system in assessing the prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2020, 36(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2020.09.014 |
| [5] | Sun Yu, Zhang HongHai, Yuan ChunWang, Li Cong, Hu CaiXia, Cui ShiChang, Zhang YongHong, Zheng JiaSheng. Change in serum level of abnormal prothrombin after microwave ablation for hepatocellular carcinoma and its clinical significance[J]. Journal of Clinical Hepatology, 2019, 35(3): 542-546. doi: 10.3969/j.issn.1001-5256.2019.03.018 |
| [6] | Chen Xiang, Wen DiGuang, You Yu, Gong JianPing. Role and mechanism of ferroptosis in treatment of liver cancer with sorafenib[J]. Journal of Clinical Hepatology, 2019, 35(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2019.10.040 |
| [7] | Sun Bin, Yang XiaoZhen, Xie Fang, Pang LiJun, Chen DeXi, Wang YanJun. Effect of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation on the survival of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 104-108. doi: 10.3969/j.issn.1001-5256.2019.01.019 |
| [8] | Yan JinZhu, Weng Hong, Zhang Chao, Wang Yuan, Yang Jian, Peng XinYu. Clinical effect and safety of percutaneous radiofrequency ablation versus microwave ablation in treatment of hepatocellular carcinoma:a Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(5): 1025-1032. doi: 10.3969/j.issn.1001-5256.2018.05.020 |
| [9] | Liang HongYuan, Guo QiYong, Mao XiaoNan, Sun Wei, Zhao Gang, Wang XiHai, Liu Zhen, Wen Feng, Lu ZaiMing. Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in treatment of hepatocellular carcinoma in high-risk locations[J]. Journal of Clinical Hepatology, 2018, 34(7): 1462-1469. doi: 10.3969/j.issn.1001-5256.2018.07.020 |
| [10] | Liu BoZhi, Yuan ZhuHui, Li Wei. A case of large hepatocellular carcinoma treated by transcatheter arterial chemoembolization combined with radiofrequency ablation[J]. Journal of Clinical Hepatology, 2018, 34(7): 1520-1522. doi: 10.3969/j.issn.1001-5256.2018.07.031 |
| [11] | Lu DongLing, Zhu YuPing, Ou Jie, Mao SuFei, Wu GuoBin, He JianBo, Huang Shan, Chen Chuang. Clinical effects of different treatment regimens for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma and influencing factors for prognosis[J]. Journal of Clinical Hepatology, 2018, 34(9): 1905-1910. doi: 10.3969/j.issn.1001-5256.2018.09.016 |
| [12] | Gao BinCheng, Guo Hui, Sun Le, Zhou Jie, Jiang DongMei. Clinical effect of two targeted drugs in treatment of advanced hepatocellular carcinoma: A comparative analysis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1689-1692. doi: 10.3969/j.issn.1001-5256.2018.08.19 |
| [13] | Wu Lei, Wang Su. Research advances in transarterial chemoembolization combined with sorafenib in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(4): 867-871. doi: 10.3969/j.issn.1001-5256.2018.04.037 |
| [14] | Luo DanDong, Qiao AnYi. Research advances in radiofrequency ablation in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1358-1361. doi: 10.3969/j.issn.1001-5256.2017.07.034 |
| [15] | Wang Peng, Ren WeiDong. Mechanism of radiofrequency ablation in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(2): 359-363. doi: 10.3969/j.issn.1001-5256.2017.02.035 |
| [16] | Zheng Kang, He MengGuo, Wang ZhiXiang. Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(5): 899-903. doi: 10.3969/j.issn.1001-5256.2016.05.017 |
| [17] | Ma JingFan, Chen Gang, Liu Hong. TACE combined with sorafenib in treatment of advanced primary hepatocellular carcinoma: a report of one case achieving complete response[J]. Journal of Clinical Hepatology, 2016, 32(1): 152-154. doi: 10.3969/j.issn.1001-5256.2016.01.030 |
| [18] | Zhang MingJuan, Liu Jia, Xiang XiaoXing, Wang Su. Research advances in sorafenib combined with orthotopic liver transplantation, radiofrequency ablation, and transarterial chemoembolization in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(8): 829-832. doi: 10.3969/j.issn.1001-5256.2014.08.037 |
| [19] | Wan YunYan, Li Ling, Huang JunLi, Huang Rong, Ying KeMan, Chen Qiang, Luo Qi, Li WenGang. Effect of sorafenib and celecoxib combination therapy on proliferation of the human cholangiocarcinoma cell line SK-ChA-1 in vitro[J]. Journal of Clinical Hepatology, 2013, 29(1): 68-71. |
| [20] | Yang Jun, Meng QingHua, Yu HongWei. Sorafenib combined with thanscatheter artierial chemoembolzation in treatment of advanced hepatocellular carcinoma: Meta analysis[J]. Journal of Clinical Hepatology, 2013, 29(10): 764-768. doi: 10.3969/j.issn.1001-5256.2013.10.011 |
DownLoad: